One of the first questions people ask about SLU-PP-332 is whether it is a peptide — it is grouped on research-chemical price lists alongside peptides, so the assumption is reasonable. The answer is no. SLU-PP-332 is a small molecule, not a peptide: it has no amino acids and no peptide bonds. It is a synthetic agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), a family of nuclear receptors, and it is the compound most often referred to in the research literature as an “exercise mimetic.” This overview covers what SLU-PP-332 actually is at the molecular level, how its mechanism works, and what published studies have measured in laboratory models.
Is SLU-PP-332 a peptide? No — here is what it is
Peptides are short chains of amino acids linked by peptide bonds; that is the defining feature of the class. SLU-PP-332 has neither. It is a small organic molecule built around a naphthalene ring system linked to a benzamide-type group, with a molar mass on the order of a few hundred grams per mole — roughly an order of magnitude smaller than even a short peptide. In chemical databases it is catalogued as a discrete small-molecule entity, not as a sequence of residues.
The reason it travels in peptide company is functional, not structural. Like many research peptides, SLU-PP-332 is studied for its effects on metabolic signaling pathways, so vendors shelve it next to them. But mechanistically it belongs to a different category: it is a receptor agonist — a drug-like molecule that binds and switches on a nuclear receptor — rather than a peptide hormone or analog. The distinction matters, because the chemistry, the targets, and the published research are all different from those of the peptides it sits beside.
What “ERR agonist” means
The three estrogen-related receptors — ERRα, ERRβ, and ERRγ — are members of the nuclear receptor superfamily. Despite the name, they are not activated by estrogen; they are “orphan” receptors that share structural similarity with the classical estrogen receptor but operate on their own program. Their job, broadly, is transcriptional control of oxidative and mitochondrial metabolism: they sit at the hub of the gene network that governs how cells generate energy.
ERRα in particular has been characterized as a master regulator of mitochondrial function, working in partnership with the coactivator PGC-1α to drive expression of genes for mitochondrial biogenesis, oxidative phosphorylation, and fatty acid handling, as reviewed in the receptor-biology literature (Ranhotra, J Recept Signal Transduct Res, 2015). SLU-PP-332 is described as a pan-ERR agonist because it activates all three receptors, with its strongest activity reported at ERRα. In plain terms: it is a chemical key designed to fit the lock that endurance metabolism normally opens.
Why it is called an “exercise mimetic”
The phrase “exercise mimetic” is a research label, not a marketing promise, and it has a specific origin. Endurance exercise activates the same PGC-1α/ERR signaling axis that SLU-PP-332 targets pharmacologically. Investigators therefore asked whether switching that axis on with a small molecule would reproduce the molecular signature of endurance training in laboratory models — and that is exactly what the founding study set out to test.
In the compound’s primary characterization, researchers reported that SLU-PP-332 produced an ERRα-dependent acute aerobic-exercise transcriptional response and, in mice, increased type IIa oxidative skeletal-muscle fibers and measured changes in exercise capacity (Billon et al., ACS Chem Biol, 2023). It is important to read that precisely: these are outcomes measured in mouse and cell models, describing what the molecule did in those experiments — not effects established in humans, and not an outcome predicted for any individual.
What published research has measured
The literature on SLU-PP-332 is preclinical — conducted in animal and cell-based systems. The findings below are reported strictly as what each cited study measured in its research model:
- Exercise-response signaling and muscle fiber type. The originating study measured an ERRα-dependent acute aerobic-exercise gene response and a shift toward oxidative muscle fibers, alongside changes in running performance, in mice (Billon et al., ACS Chem Biol, 2023).
- Metabolic-syndrome model. A follow-up study in mouse models of metabolic syndrome measured increased energy expenditure and changes in insulin sensitivity and body composition after administration of the ERR agonist (Billon et al., J Pharmacol Exp Ther, 2024).
- Cardiac metabolism. In a pressure-overload heart-failure model, pan-ERR agonists including SLU-PP-332 were measured to enhance cardiac fatty-acid metabolism and mitochondrial function and to improve cardiac measures in the treated animals (Xu et al., Circulation, 2024).
- Underlying receptor biology. The transcriptional machinery these effects run through — ERRα’s control of mitochondrial and oxidative-metabolism genes — is documented in the broader receptor-biology literature (Ranhotra, J Recept Signal Transduct Res, 2015).
Across all of this work, the common thread is the oxidative-metabolism gene program: SLU-PP-332 engages ERR, and ERR turns on the mitochondrial and fatty-acid-metabolism transcripts. What the molecule does downstream of that has been characterized only in non-human research systems to date.
How it relates to the BAM-SLU blend
SLU-PP-332 also appears as a named component of the BAM-SLU Melt blend that contains it, where it is combined with other research compounds in one preparation. As with any blend, the SLU-PP-332 portion is the same small-molecule ERR agonist described here — the blend simply co-locates it with separate molecules that each carry their own chemistry and literature. For understanding what SLU-PP-332 itself is, the single-compound profile on this page is the relevant reference.
Frequently asked questions
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small organic molecule — a synthetic agonist of the estrogen-related receptors (ERRα/β/γ). It contains no amino acids and no peptide bonds, so it is not a peptide despite often being listed alongside research peptides.
What does SLU-PP-332 do at the molecular level?
It binds and activates the estrogen-related receptors (ERRα, ERRβ, and ERRγ), with its strongest reported activity at ERRα. Those receptors are transcription factors that regulate genes for mitochondrial function and oxidative metabolism, which is why the compound is studied as a metabolic-pathway tool.
Why is SLU-PP-332 called an “exercise mimetic”?
Because it activates the same PGC-1α/ERR signaling axis that endurance exercise activates. In the originating mouse study it reproduced an acute aerobic-exercise transcriptional response and shifted muscle toward oxidative fibers (Billon et al., 2023). The term describes a molecular resemblance measured in research models, not a guaranteed effect in any individual.
Are SLU-PP-332 and the ERR receptors related to estrogen?
Only by name and structural similarity. The estrogen-related receptors are “orphan” nuclear receptors that resemble the classical estrogen receptor but are not activated by estrogen and instead govern energy-metabolism gene programs.
Has SLU-PP-332 been studied in humans?
The published research on SLU-PP-332 is preclinical — carried out in animal and cell-based models. The exercise-response, metabolic-syndrome, and cardiac-metabolism findings cited here were all measured in those research systems, not in human subjects.
What is SLU-PP-332 derived from?
It is a synthetic ERR agonist developed through medicinal-chemistry optimization of earlier ERR-active scaffolds. The result is a small-molecule pan-ERR agonist used as a research tool to probe estrogen-related-receptor signaling.
References
- Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. 2023. PMID: 36988910.
- Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024. PMID: 37739806.
- Xu W, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024. PMID: 37961903.
- Ranhotra HS. Estrogen-related receptor alpha and mitochondria: tale of the titans. Journal of Receptor and Signal Transduction Research. 2015. PMID: 25222219.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
